title: Invasive streptococci.
abstract: Before the introduction of antibiotics, serious infections caused by Streptococcus pyogenes (Lancefield Group A streptococci) were common. Before World War II, this bacterium was responsible for as many as 50% of postpartum deaths and was the major cause of death in patients with burns. Also common were the sequelae of streptococcal infections-rheumatic fever and post-streptococcal glomerulonephritis. With the use of penicillin, however, Streptococcus pyogenes was believed to be virtually eliminated as a pathogen. The organism was consigned to the history books, but not for long. In the mid-1980s, focal resurgences of rheumatic fever began to be reported from different areas in the USA, such as Salt Lake City, Utah. In such communities, where increases in cases of rheumatic fever had been reported, the serotypes M-1, 3, 5, 6 and 18 were isolated which, on culture, produced characteristic mucoid colonies. At the same time, reports of increases in invasive streptococcal disease began to surface in both the USA and Europe. Two syndromes were described; invasive streptococcal infection, occurring in previously healthy children and adults, commonly associated with septicaemia resulting from a deep focus of infection such as bone or lung; and streptococcal toxic shock syndrome, involving a cutaneous focus, accompanied by necrotizing or bullous soft tissue changes. Septicaemia is rare in streptococcal toxic shock syndrome, but the most characteristic feature is one of rapidly progressing multi-organ failure. A high proportion of the strains of Streptococcus pyogenes associated with this condition are serotype M-1, and fatality rates approaching 50% have been reported.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Microbiology, Bristol Royal Infirmary, UK.
authors.forename: R C
authors.initials: RC
authors.lastname: Spencer
mesh_terms: D016470:Bacteremia / Q000453:epidemiology; D004917:Erythromycin / Q000627:therapeutic use; D014943:Global Health; D006801:Humans; D010406:Penicillins / Q000627:therapeutic use; D012541:Scarlet Fever / Q000453:epidemiology; D012772:Shock, Septic / Q000453:epidemiology; D017192:Skin Diseases, Bacterial / Q000453:epidemiology; D013290:Streptococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D013297:Streptococcus pyogenes / Q000472:pathogenicity*
chemical_list: D010406:Penicillins; D004917:Erythromycin